Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer

Abstract

IMPORTANCE Different adjuvant chemotherapy regimens are available for early-stage breast cancer. Because conventional meta-analysis does not allow comparing all regimens, we performed a network meta-analysis to identify the most effective adjuvant chemotherapy regimen. OBJECTIVE To find the most effective adjuvant therapy regimen for early-stage breast cancer. DATA SOURCES We searched MEDLINE, Embase, and the Cochrane Library for articles published before June 2015; the American Society of Clinical Oncology annual meeting abstracts from January 1983 through December 2014; and the American Association for Cancer Research annual meeting abstracts from January 1916 through December 2014. Additionally, we manually searched bibliographies for related references. STUDY SELECTION We included randomized clinical trials of adjuvant treatments for early-stage breast cancer that compared 2 or more of the following: no adjuvant chemotherapy; sequential anthracycline-cyclophosphamide and taxane (AC-T); concurrent anthracycline-cyclophosphamide and taxane (ACT); anthracycline-cyclophosphamide without taxane (AC); docetaxel and cyclophosphamide (TC); cyclophosphamide, methotrexate, and fluorouracil (CMF); and platinum-containing regimens. DATA EXTRACTION AND SYNTHESIS We followed the PRISMA guidelines. Two investigators independently selected the articles and extracted information. Disagreements were resolved by discussion with another author. Quality was assessed by Cochrane risk-of-bias method. Data were pooled using random-effects models. MAIN OUTCOMES AND MEASURES We used network meta-analysis to test the most effective adjuvant therapy regimen in terms of overall survival (OS) by comparing regimens listed in the National Comprehensive Cancer Network guidelines and platinum-containing regimens. RESULTS We identified 24 trials. The TC and platinum-containing regimens had OS benefit similar to that of sequential AC-T (TC hazard ratio [HR], 0.93; 95%CI, 0.62–1.40; and platinum HR, 0.93; 95%CI, 0.66–1.31). Patients treated with CMF or AC had significantly worse OS than those treated with sequential AC-T (CMF HR, 1.56; 95%CI, 1.32–1.85; and AC HR, 1.22; 95%CI, 1.10–1.37). Platinum-containing regimens tended to be more toxic than sequential AC-T. The toxicity of TC was similar to or less than that of sequential AC-T. Meta-regression analysis showed that hormone receptor status did not impact the HRs for OS for any regimen. CONCLUSIONS AND RELEVANCE Sequential AC-T is likely to be the most effective adjuvant therapy regimen for early-stage breast cancer regardless of hormone receptor status.

A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL)

“…When we grouped the regimens by relative toxicity (according to DLH, a breast oncologist), they fell into the same three categories. The rankings by toxicity were consistent with the risk of hospitalization by adjuvant regimen as estimated from population-based administrative databases by Barcenas et al [22], and also with adverse effect estimates in a meta-analysis by Fujii et al [23]. When we conducted our analyses, we found that categories 2 and 3 were homogeneous with regard to outcomes (data not shown), so we combined them for all analyses as category 2/3.…”

Perceptions of Vascular Access for Intravenous Systemic Therapy and Risk Factors for Lymphedema in Early-Stage Breast Cancer—A Patient Survey

“…When looking at the choice of chemotherapy regimen, it appears that our centres used fec-d more often in the adjuvant setting than has been reported in systematic reviews 17 . The reported rates of trastuzumab use were also slightly higher than published rates, although many patients were unsure and likely did not receive trastuzumab 18 .…”

Toxicity and Pharmacogenomic Biomarkers in Breast Cancer Chemotherapy

“…Adding taxanes to breast cancer chemotherapy regimens in the neoadjuvant, and the adjuvant setting was found to significantly enhance the pathological response and overall survival, respectively (Hertz et al, 2014). A meta-analysis that included 28,853 patients from 24 trials concluded that the chemotherapy regimen composed of doxorubicin, cyclophosphamide and followed by paclitaxel (known as AC-T) is the most effective adjuvant therapy in early breast cancer (Fujii et al, 2015).…”